Critical issues of HIV treatment in the era of highly active antiretroviral therapy

Expert Opinion on Investigational Drugs

Volumn 10, Issue 2, 2001, Pages 175-183

  Battegay, M ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Antiretroviral therapy; HIV; Resistance; Salvage

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; 2 ETHYL 7 FLUORO 1,2,3,4 TETRAHYDRO 3 OXO 1 QUINOXALINECARBOXYLIC ACID ISOPROPYL ESTER; 2' DEOXY 3' OXA 4' THIOCYTIDINE; 2',3' DIDEOXY 2' FLUOROADENOSINE; 6 CHLORO 2 [(1 FURO[2,3 C]PYRIDIN 5 YLETHYL)THIO] 4 PYRIMIDINAMINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CALANOLIDE A; CAPRAVIRINE; CD4 ANTIGEN; CI 1012; DELAVIRDINE; EMIVIRINE; EMTRICITABINE; ENFUVIRTIDE; LOPINAVIR; MOZENAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; T 1249; TALVIRALINE; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE; ZINTEVIR;

CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; EDITORIAL; FATIGUE; GLUCOSE INTOLERANCE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIPODYSTROPHY; LONG TERM CARE; LYMPHOCYTE COUNT; NAUSEA; PERIPHERAL NEUROPATHY; REBOUND; REFERENCE VALUE; SALVAGE THERAPY; SIDE EFFECT; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT INDICATION; VIREMIA; VIRUS DETECTION; VIRUS LOAD; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; SALVAGE THERAPY;

EID: 0035150615     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.2.175     Document Type: Editorial

References (22)

1. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
4. Time to hit HIV, early and hard
5. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
6. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
7. Immune restoration with antiretroviral therapies
8. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study
9. Immune control of HIV-1 after early treatment of acute infection
10. Effect of ritonavir on saquinavir metabolism
11. Early participation in a HIV cohort study slows disease progression and improves survival. The Swiss HIV Cohort Study
12. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival
13. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: A cohort study
14. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study
15. Management of the adverse effects of antiretroviral therapy and medication adherence
16. Therapeutic drug monitoring of antiretroviral agents
17. Why is Highly Active Antiretroviral Therapy (HAART) not prescribed or discontinued?
18. Durability and reasons for discontinuation of first highly active antiretroviral therapy (HAART) in a cohort of proteinase inhibitor naive HIV-infected patients
19. The Swiss HIV Cohort Study: Effect of antiretroviral therapy on viral load and lymphocyte numbers in an unselected cohort of HIV-infected individuals
20. HIV-protease inhibitors
21. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pretreated HIV-1 infected patients
22. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection